Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

Document › Details

UCB S.A.. (2/28/19). "Press Release: UCB Full Year Report 2018. 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB’s Strong Pipeline". Brussels.

	Organisation	UCB S.A. (Euronext: UCB)
	Group	UCB (Group)
	Product	Cimzia®
	Product 2	Vimpat®
	Person	Tellier, Jean-Christophe (201403– CEO-elect joined UCB 2011 before Ipsen + Macrogenics + Novartis)
	Person 2	Witte, Antje (UCB 201601 Investor Relations)

Original document
accessed by [iito] on 2019-03-01

Record changed: 2019-03-06

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for UCB (Group)

[1] UCB S.A.. (11/12/20). "Press Release: UCB Strengthens Its Gene Therapy Activities with Additional Pipeline Programs, Capabilities and Platforms". Brussels....
[2] UCB S.A.. (3/9/20). "Press Release: UCB Announces Appointment of Sandrine Dufour as New Chief Financial Officer". Brussels....
[3] CRISPR Therapeutics AG. (2/26/20). "Press Release: CRISPR Therapeutics Proposes Changes to the Board of Directors". Zug & Cambridge, MA....
[4] UCB S.A.. (10/10/19). "Press Release: UCB Agrees to Acquire Ra Pharmaceuticals". Brussels & Cambridge, MA....
[5] Rinri Therapeutics Ltd.. (5/20/19). "Press Release: Rinri Therapeutics Secures £1.4 Million Seed Funding to Advance Its Novel Regenerative Cell Therapy to Treat Sensorineural Hearing Loss". Sheffield....
[6] UCB S.A.. (4/9/19). "Press Release: FDA Approves Evenity (Romosozumab) for the Treatment Of Osteoporosis in Postmenopausal Women at High Risk for Fracture". Brussels....
[7] UCB S.A.. (3/1/19). "Press Release: New Data Affirms Strength of UCB Immuno-Dermatology Portfolio". Brussels....
[8] UCB S.A.. (2/15/19). "Press Release: UCB Builds on Its R&D Footprint to Form a Research Satellite Facility within King’s College London". Brussels & Slough....
[9] UCB S.A.. (2/11/19). "Press Release: UCB and Epilepsy Society Announce Pioneering UK Genomics R&D collaboration". Slough & Brussels....
[10] UCB S.A.. (7/13/18). "Press Release: UCB and Amgen Resubmit Biologics Licence Application (BLA) for Evenity (Romosozumab) to the U.S. FDA". Brussels & Thousand Oaks, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top